DuPont's first-quarter results top expectations
DuPont announced its results for the first quarter of 2023, and the company's first-quarter performance exceeded expectations.
The performance report shows that DuPont's first-quarter revenue fell 8% year-on-year to $3 billion, higher than the expected $2.94 billion; operating profit before interest, taxes, depreciation and amortization (EBITDA) was $714 million; adjusted earnings per share in the first quarter Earnings came in at $0.84, beating estimates by $0.8. For the second quarter, the company expects net sales of approximately $3.02 billion and EPS of approximately $0.84. For 2023, the company expects net sales of US$12.3 billion to US$12.5 billion; earnings per share of US$3 to US$3.7.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-09-01
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Another Strategic Move! DuPont Launches a New Specialty Lubricants Project in Zhangjiagang
-
DuPont Bids Farewell to Its Aramid Business with a $1.8 Billion Sale
-
DuPont Launches Silver Nanowire Products in Korea
-
DuPont Plans to Divest the Electronics Business on November 1, 2025
-
DuPont and Zhen Ding Technology join hands to promote the development of high-end printed circuit board technology
-
Deltech Takes Over Divinylbenzene Production from DuPont
-
DuPont Acquires Donatelle Plastics
-
DuPont to split into three companies, CEO Brin resigns
-
DuPont launches Tyvek TrifectaA2 fire-resistant breathable membrane
-
Joined Forces! DuPont and Nippon Paint Jointly Launch PVF Coating Solutions
Recommend Reading
-
![Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025]()
Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025
-
![From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds]()
From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds
-
![Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025]()
Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025
-
![From Modest Gains to Massive Profits: Nutrien’s Q3 2025 Marks a Stunning Agricultural Comeback]()
From Modest Gains to Massive Profits: Nutrien’s Q3 2025 Marks a Stunning Agricultural Comeback
-
![Yara’s Green Surge: Record Profits Fuelled by Precision, Not Just Prices]()
Yara’s Green Surge: Record Profits Fuelled by Precision, Not Just Prices
-
![Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger]()
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
![China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot]()
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
![Downstream Demand Releases, Formic Acid Prices Steadily Rise]()
Downstream Demand Releases, Formic Acid Prices Steadily Rise
-
![Market Slump and Disappearance of Premium Lead to Significant Decline in Phthalic Anhydride Prices in China]()
Market Slump and Disappearance of Premium Lead to Significant Decline in Phthalic Anhydride Prices in China
-
![Lithium Carbonate Officially Enters the Core Track of Global Strategic Reserves]()
Lithium Carbonate Officially Enters the Core Track of Global Strategic Reserves
